France's research-based pharmaceutical association, the LEEM, has published its biennial investigation into the state of clinical research for industrial purposes. The 2008 edition of the report found that France's position in global terms is broadly maintained, although there is a relative decline versus the rest of Europe. The study was conducted with 19 international innovative drugmakers, including eight of the world's top 10. In order to maintain national competitiveness, the LEEM proposes a five-point plan for the future.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze